Dan Hurley investigates. Why a focus on genetics hasn’t paid off as much as hoped: Gleevec, used since 2001 to treat chronic myelogenous leukemia (C.M.L.) and a variety of other cancers, is often pointed to as one of the great gene-to-medicine success stories. Its design followed logically from the identification of an abnormal protein caused […]
An interesting read via The Dish
No comments:
Post a Comment